Tracheomalacia and tracheomegaly in infants and children with congenital diaphragmatic hernia managed with and without fetoscopic endoluminal tracheal occlusion (FETO): a multicentre, retrospective cohort study

Who's speaking

• Carlos Colunga — host

Chapters

• 0:00Introduction and Study Design — Introduction to the topic of tracheal occlusion risks in CDH and overview of the multi-center cohort study methodology comparing outcomes with and without FETO.
• 0:22Key Findings — Presentation of three main findings: increased tracheomalacia prevalence with resolution timeline, increased tracheal diameter, and retained balloon components.
• 0:46Conclusion — Summary of risk-benefit profile of FETO: effective for lung growth but associated with higher tracheomalacia risk that appears to resolve.

Key claims

• 0:24Tracheomalacia was 5% more common in tracheal occluded infants with 4% more cases — Carlos Colunga
• 0:29Tracheomalacia symptoms typically receded within 55 months in FETO-treated infants — Carlos Colunga
• 0:33FETO-treated infants showed a larger trachea, approximately 31% wider — Carlos Colunga
• 0:3337% of tracheally occluded cases retained metallic balloon components — Carlos Colunga
• 0:33No significant complications were reported from retained metallic balloon components — Carlos Colunga
• 0:46Tracheal occlusion is effective in promoting lung growth — Carlos Colunga
• 0:46FETO is associated with a higher risk of tracheomalacia — Carlos Colunga
• 0:46Most cases of FETO-associated tracheomalacia resolve and do not appear to have long-term effects — Carlos Colunga

Open questions

• What are the long-term clinical implications of retained metallic balloon components in 37% of FETO cases?
• What is the mechanism by which FETO leads to increased tracheal diameter (31% wider)?
• Are there predictive factors for which FETO-treated infants will develop tracheomalacia?